A novel vaccine treatment for skin cancer melanoma has showed exceptionally encouraging outcomes in a recent research.

According to the research, the vaccination had an overall survival rate of 96 percent.

Moderna and Merck & Co. created the vaccine, which was announced alongside the Keytruda medication.

READ MORE: Morgan Spurlock, The Filmmaker Of “Super Size Me,” Died At The Age Of 53 After A Battle With Cancer

It boosted patients’ odds of survival while also demonstrating long-term effectiveness.

The trial involved 157 patients over a two-and-a-half year period.

It discovered that melanoma patients who received the vaccine combination had an overall survival rate of 96%.

This was compared to 90.2% for those who solely took Keytruda.

When it comes to recurrence, around 75 percent of patients who received the vaccine did not experience a recurrence.

Meanwhile, 55.6% of individuals who solely received Keytruda did not experience a recurrence.

READ MORE: OJ Simpson Dead At The Age Of 76 After A Battle With Cancer

A December analysis found that people taking the combination had a 49 percent lower risk of recurrence or mortality than those taking Keytruda alone.

This had a median follow-up time of little under three years.

While it is presently only being investigated for melanoma, it may have uses in other types of cancer.

Professor Georgina Long, co-director of the Melanoma Institute Australia, told Sky News that “this has the potential to transform cancer treatments around the world.”

“The study results have a transformational impact not only on melanoma treatment, but also on other cancers.

“This phase III trial is the first of its kind and represents one of the most significant developments not only in melanoma, but in the entire cancer field.”

“Our next step is to refine who gets what immunotherapy before surgery, as some patients will need combination and others will not.”

Merck and Moderna have been working together since 2016, and they are currently conducting a trial to investigate the late stage of the Keytruda-new vaccine combo.

But how does a ‘cancer vaccine’ work?

READ MORE: Country Singer-Songwriter Toby Keith Passes Away At Age 62 Following A Diagnosis Of Stomach Cancer

A conventional vaccination infects a patient with a weakened version of a virus in order to establish immunity, whereas cancer is caused by cells mutating and multiplying uncontrollably.

So this is not the same as other vaccines, and it is known as mRNA vaccine technology.

To treat cancer, the vaccination contains instructions for the cells to produce a specific protein.

This varies by individual and can be utilized to prevent cancer-causing mutations.